2 results
Approved WMOCompleted
To increase progression-free survival at 3 months.
Approved WMOPending
To evaluate the efficacy of AD 923 in comparison to MSIR in the management of breakthrough pain in subjects with malignicies who are taking a stable dose of background opioids.